Who We Are2018-08-24T17:06:01+00:00

Singulex Is Revolutionizing Immunodiagnostics to Transform Healthcare

Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Singulex Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. The Singulex Clarity system and Singulex Clarity assay received CE mark in 2017 and are commercially available in Europe; additional assays to detect and rule out infectious and inflammatory diseases are in development. Singulex is also developing a point-of-care platform and exploring applications beyond the clinical setting.

* Singulex Clarity system is in development and is not yet available for commercial sale in the United States.
Guido Baechler
Guido BaechlerPresident and Chief Executive Officer
Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.

Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.

John Todd, Ph.D.
John Todd, Ph.D.Chief Scientific Officer
John Todd joined Singulex in 2007 and has championed Singulex’s clinical programs to demonstrate the clinical utility of SMC™ for cardiovascular disease risk prediction and patient management. John has substantial diagnostics development experience, having developed products to address unmet clinical needs in numerous disease areas and successfully establishing their medical advantage.

Prior to joining Singulex, John held leadership and executive positions at numerous healthcare companies including Chiron Diagnostics, Bayer Diagnostics, Baxter Healthcare, NUGEN Technologies, Protogene Labs and ENZO Biochem. He has co-authored over 60 peer-reviewed publications and 90 scientific abstracts, been issued 15 patents and presented at over 100 biomedical scientific conferences. John has received 6 SBIR grants for the development and commercialization of diagnostic products.

John received a Ph.D. in Biochemistry and a B.S. in Biology from the University of Southern California, followed by post graduate training in Cell and Molecular Biology at the Sabatini Lab, New York University Medical Center.

Brandon Hants
Brandon HantsChief Financial Officer
Brandon has served as Chief Financial Officer since 2018. Since joining Singulex in 2012 as Director of Financial Planning & Analysis, Brandon has accepted roles of increasing responsibility including oversight of Medical Billing, IT, Supply Chain, Legal and Facilities. Prior to Singulex, Brandon spent three years in a finance capacity at Novartis Vaccines & Diagnostics. Prior to that, Brandon spent ten years at Genentech working in the areas of Finance, Accounting, Treasury & Supply Chain.

Brandon received a B.S. degree in Cell & Developmental Biology from the University of California at Santa Barbara. He also earned an M.B.A. with Finance emphasis from the University of San Francisco.

Jeffrey Bishop, Ph.D.
Jeffrey Bishop, Ph.D.Senior Vice President, Diagnostics Operations
Jeff Bishop joined Singulex in 2013. Jeff has worked in the diagnostics industry for more than 13 years at Biosite, Inverness Medical Innovations and Alere. During this time, Jeff held various scientific and leadership positions within the R&D organization including Vice President of R&D for Point of Care platforms and Vice President of R&D for Drugs of Abuse platforms. Jeff has extensive experience working with biomarkers and has led the development of many drug and biomarker assays on numerous platforms across a wide range of disease states.

Jeff earned both an M.S. and a Ph.D. in Bioengineering from the University of California, San Diego and holds a B.S. in Chemical Engineering from Brigham Young University. He also holds an RAC certification in Regulatory Affairs.

Jessica McCarthy
Jessica McCarthyVice President, Global Marketing & Communications
Jessica McCarthy joined Singulex in 2016, responsible for the company’s brand, worldwide product and service launches and all advertising and promotion. She brings more than 20 years of experience building effective marketing teams and executing successful, high-growth marketing strategies. Prior to Singulex, Jessica held leadership roles of increasing responsibility at Blue Shield of California, and was most recently Vice President of Integrated Marketing and Customer Experience. Before that, she was a marketing lead at Silicon Valley Bank and managed Fortune 500 and start-up accounts at several global advertising agencies.

Jessica earned a BA in Religion and Art History from Syracuse University and completed the Women’s Senior Leadership Program at Northwestern University’s Kellogg School of Management. In 2014, The San Francisco Business times named her one of the “Most Influential Women in the Bay Area,” and inducted her into the “Most Influential Women in the Bay Area Hall of Fame” in 2015.

Patricia Ryan
Patricia RyanCompliance Officer
Patricia Ryan joined Singulex in 2014, bringing over 20 years of experience focused on the internal control environment. Most recently, Patty served as the Latin American and Asia Pacific Regional Compliance Officer for Novartis Vaccines & Diagnostics as well as the U.S. Compliance Officer for the Diagnostics business, providing compliance support in all aspects of commercial activities. Patty joined Novartis Vaccines & Diagnostics as a Sarbanes- Oxley Compliance; Internal Controls Analyst. Patty also spent several years as a Corporate Internal Auditor for AT&T.

Patty has worked for over a decade in local Public Accounting Firms in the San Francisco Bay area leading auditing and consulting service engagements. Patty holds a B.S. in Business Administration with a concentration in Accounting from San Jose State University. She is a Certified Public Accountant and a Certified Internal Auditor.

Byron Clendenen
Byron ClendenenVice President, Human Resources
Byron Clendenen joined Singulex in 2014 and possesses 25 years of HR leadership experience. Previously, Byron served and led HR functions in diverse settings such as CollabNet, Inc., within the enterprise cloud development software tools & services space; Vpacket Communications within the VoIP telecom space; Integrated Systems within the embedded software space; and Toshiba America MRI within the medical diagnostic imaging space.

Byron has contributed in privately and publicly held settings, and has developed, managed, and refined HR functions and programs for start-ups as well as for mature, multi-national organizations.

Byron earned a B.A. in Psychology from the University of California, Berkeley, and an M.A. in Psychology from San Francisco State University. He additionally possesses SPHR certification.

Darin Leigh
Darin LeighVice President, Global Sales
Darin Leigh has joined Singulex in 2018. Darin has worked in the life science and IVD industries for over 25 years, for Abbott, Luminex, Asuragen and Metabalon; in senior roles focusing on commercial operations, global sales and marketing. As a senior executive, he has extensive experience in building commercial businesses from the group up, and delivering accelerated sales growth and profitability.

Darin earned a degree in Medical Laboratory Sciences from Paddington College, University of London, United Kingdom.

Guido Baechler
Guido BaechlerPresident and Chief Executive Officer
Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.

Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.

David Ian Bell
David Ian BellChief Innovation Officer, Grifols
David Ian Bell is the Chief Innovation Officer for Grifols S.A. Additionally, he is the President and Chief Executive Officer of Grifols Innovation and New Technology Limited (GIANT). He also serves as General Counsel with responsibility for, among other things, mergers and acquisitions and new business development. Mr. Bell serves on Grifols Corporate, Bioscience, Diagnostic and Hospital Executive Committees and is on the Board of Directors of numerous Grifols’ portfolio companies including Alkahest, Aradigm, Singulex, and Araclon.

Prior to joining Grifols in 2003, Mr. Bell served as General Counsel and Vice President of Alpha Therapeutic Corporation following more than 20 years as a corporate lawyer specializing in healthcare, pharmaceutical and biotechnology regulation and liability. Mr. Bell attended the University of California, Irvine focusing on Psychobiology (Neuroscience), Southwestern University School of Law and a postgraduate program at Harvard Law School.

Heiner Dreismann, Ph.D.
Heiner Dreismann, Ph.D.Lead Director
Heiner Dreismann, Ph.D. has been a member of our board of directors since June of 2007 and has over 26 years of experience in biotech and healthcare companies. Since May of 2008, Dr. Dreismann has served as Interim Chief Executive Officer of GeneNews Limited, a public diagnostics company. From 2001 until 2006, Dr. Dreismann served as President and Chief Executive Officer of Roche Molecular Systems, Inc., a division of Hoffmann-La Roche Ltd., or Roche, focused on clinical molecular diagnostics.

Before serving in these roles, he held various management positions in Roche, among them Head of Integration Office Diagnostics and Head of Global Business Development for Roche Diagnostics. Dr. Dreismann currently serves on the boards of directors of Ignyta, Inc., Myriad Genetics, Inc., Med BioGene Inc. and GeneNews Ltd., each a public company in the life sciences or healthcare diagnostics sectors. Dr. Dreismann received his M.A. in Biology and his Ph.D. in Microbiology / Molecular Biology both from Westfaelische Wilhelms University (The University of Münster) in Germany. Dr. Dreismann brings to our board of directors significant expertise in the biotech and healthcare sectors from both his advanced degree and from previous executive leadership positions. In addition, Dr. Dreismann’s experience as a Director of public life sciences companies provides the board of directors with valuable insights to assist in achieving our goals.

Carl L. Gordon, Ph.D., CFA
Carl L. Gordon, Ph.D., CFAGeneral Partner, OrbiMed and Co-Head, Private Equity
Carl Gordon, Ph.D., CFA has been a member of our board of directors since June of 2007. Dr. Gordon co-founded OrbiMed Advisors LLC, or OrbiMed, where he serves as a General Partner and Co-Head of Private Equity. He is experienced in both private equity and small-capitalization public equity investments. Prior to his experience at OrbiMed, Dr. Gordon was a senior biotechnology analyst at Mehta and Isaly, a pharmaceutical consulting firm and predecessor to OrbiMed, from 1995 to 1997.

From 1993 to 1995, Dr. Gordon was a fellow at The Rockefeller University. He received his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and a bachelor’s degree from Harvard College.

From August 2009 until June 2012, Dr. Gordon also served on the board of directors of Complete Genomics, Inc., a life sciences company. As a venture capitalist focused on life science companies who sits on numerous boards, Dr. Gordon provides financial and operational expertise regarding our industry. In addition, Dr. Gordon provides substantial expertise in the particularly relevant scientific field of molecular biology, and his financial credentials are valuable toward his service on our audit committee.

Stephen L. Rose, CPA, CMA
Stephen L. Rose, CPA, CMADirector, Fisk Ventures, LLC
Steve Rose, CPA, CMA, has been a member of our board of directors since September, 2004. Mr. Rose, who has over 17 years of experience in venture investing, is Managing Director of Fisk Ventures, LLC, the venture investment company for H. Fisk Johnson, Ph.D., Chairman of the Board, Chairman and Chief Executive Officer of S.C. Johnson and Son Inc., or S.C. Johnson. In this capacity, Mr. Rose serves on the boards of several early stage technology-based companies. Mr. Rose previously held several positions with S.C. Johnson in both the United States and in Canada, including positions in strategic planning, new business and new product development, and financial and business management.

Mr. Rose has an Honors Bachelor of Commerce from McMaster University, and is also a Certified Management Accountant. As a venture capitalist with experience on the boards of several emerging companies, Mr. Rose provides the Singulex Board of Directors with insightful and relevant expertise in both finance and operations. In addition, his financial credentials and experience are of significant value in his service on our governance committee.

Fred K. Vogt
Fred K. VogtPresident, FKV Enterprises, LLC
Fred Vogt has been a member of our board of directors since our incorporation in 2002. Mr. Vogt has 28 years of operations and manufacturing experience in the pharmaceutical industry, and he currently provides consulting services to senior management executives through FKV Enterprises LLC. From 1997 until 2000, Mr. Vogt served as a Senior Vice President of Specialty Chemicals at Tetra Technologies Inc., a chemical manufacturer.

Prior to this experience, he worked for 25 years for Mallinckrodt, Inc., a chemical and pharmaceutical company, in a variety of manufacturing and business positions. Mr. Vogt has a bachelor’s degree in Chemical Engineering, a master’s degree in Engineering Administration and Honorary Professional Chemical Engineering degree from the University of Missouri at Rolla.